Back to School: How biopharma can reboot drug development. Access exclusive analysis here

DSTP3086S: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 28 patients with CRPC showed that the recommended Phase II dose of IV DSTP3086S was 2.8

Read the full 241 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE